The Contrast Media Injectors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Contrast Media Injectors Market:
https://www.thebusinessresearchcompany.com/report/contrast-media-injectors-global-market-report
According to The Business Research Company’s Contrast Media Injectors Global Market Report 2024, The contrast media injectors market size has grown strongly in recent years. It will grow from $1.6 billion in 2023 to $1.72 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increased incidence of chronic diseases, increased diagnostic imaging procedures, demand for minimally invasive procedures, expansion of healthcare infrastructure, growing aging population.
The contrast media injectors market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rise in interventional radiology procedures, increasing prevalence of cancer, focus on patient safety and comfort, globalization of healthcare services, regulatory support and compliance. Major trends in the forecast period include automation and connectivity, emergence of dual-head injectors, advancements in injector technology, focus on patient safety, rise in interventional radiology procedures, enhanced imaging techniques and modalities.
Increasing cancer and cardiovascular disease (CVD) are expected to propel the growth of the contrast media injectors market going forward. Cancer is a condition that occurs when body cells grow out of control and spread to other body regions. Cardiovascular disease refers to a type of disease that affects the heart or blood vessels. Contrast media injectors are applied while diagnostic imaging to enhance image quality and patient safety and improve blood flow and tissue perfusion. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth of 3.16%. , Furthermore, in April 2023, according to the World Heart Federation, a Switzerland-based non-governmental organization, over 500 million individuals worldwide will remain impacted by cardiovascular diseases. These conditions led to 20.5 million fatalities in 2021, representing nearly one-third of the total global mortality and reflecting a notable rise from the previously estimated 121 million deaths attributed to cardiovascular diseases. Therefore, increasing cancer and cardiovascular disease (CVD) are driving the growth of the contrast media injectors market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10187&type=smp
The contrast media injectors market covered in this report is segmented –
1) By Product: Consumables, Injector Systems, Accessories
2) By Type of Injectors: Single Head Injectors, Dual-Head Injectors, Syringe less Injectors
3) By Application: Radiology, Interventional Cardiology, Interventional Radiology
4) By End-user: Hospitals, Diagnostics Centers, Ambulatory Surgery Centers
Strategic partnerships are a key trend gaining popularity in contrast media injectors market. Major companies operating in the contrast media injectors market are forming partnerships to develop a new type of relationship in which two or more organizations have similar product developments. For instance, in December 2022, Qaelum NV, a Belgium-based advanced dose and contrast management software solutions company, partnered with Ulrich GmbH & Company KG., a France-based manufacturer and distributor of surgical instruments. With this partnership, the companies aim to combine their advanced contrast management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks. Furthermore, in December 2021, Bracco Group, an Italy-based healthcare company, announced a partnership with Guerbet, a France-based manufacturer of contrast agents. This partnership aim is to develop Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent and to strengthen expertise and investigate untapped areas of research in pursuit of an agent that would enable early identification and provide significant health advantages.
The contrast media injectors market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
